As patents on proprietary medicines increasingly continue to expire, the pressure on pharmaceutical supply chains continues to rise to meet business expectations and outcomes. In late November, the very popular cholesterol-lowering drug Lipitor, which at its peak, generated over $12.9 billion in global revenues, became open for production by generic drug manufacturers. Generic drug producers...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to Drug Patent Expirations Adding More Challenges to Pharmaceutical Supply Chains
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account
account